Contact
searchSearch
HMP Global
Login

Skin Cancer Resource Center

Farberg
Videos
Co-Managing Advanced Skin Cancer: Immunotherapy Insights
01/25/2024
Aaron S. Farberg, MD
In this interview, Dr Aaron Farberg explored key factors in advanced basal cell carcinoma and cutaneous squamous cell carcinoma.
In this interview, Dr Aaron Farberg explored key factors in advanced basal cell carcinoma and cutaneous squamous cell carcinoma.
In this interview, Dr Aaron...
01/25/2024
The Dermatologist
From The Dermatologist
Trending From ACCC
Improving the Care of Patients With Advanced Nonmelanoma Skin Cancers
02/06/2023
In 2022, the Association of Community Cancer Centers (ACCC) developed the Advanced Non-Melanoma Skin Cancers Visiting Experts Program to educate multidisciplinary providers through interactive, virtual discussions on effective practices for...
In 2022, the Association of Community Cancer Centers (ACCC) developed the Advanced Non-Melanoma Skin Cancers Visiting Experts Program to educate multidisciplinary providers through interactive, virtual discussions on effective practices for...
In 2022, the Association of...
02/06/2023
Journal of Clinical Pathways
Quiz
Quiz: Ipilimumab for the Treatment of Metastatic Melanoma
07/29/2021
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line...
07/29/2021
Journal of Clinical Pathways
Conference Coverage
Toxicity Costs Among Patients With Melanoma Receiving Ipilimumab and Nivolumab
07/14/2021
Study findings show the cost of toxicities among patients with metastatic melanoma receiving ipilimumab and nivolumab were small, encompassing 3% of total costs.
Study findings show the cost of toxicities among patients with metastatic melanoma receiving ipilimumab and nivolumab were small, encompassing 3% of total costs.
Study findings show the cost of...
07/14/2021
Journal of Clinical Pathways
Research Reports
Pediatric Sunscreen Coverage by Medicaid as a Primary Prevention Strategy to Reduce Melanoma Burden: A Cost-Effectiveness Analysis
04/22/2021
Christine T. Lauren, MD; Richard D. Carvajal, MD; Connor Stonesifer, BA; Chin Hur, MD, MPH; Robert Stern, MD; Daniel C. Malone, RPh, PhD, FAMCP; Larisa J. Geskin, MD; Megan H. Trager, MD; Dawn Queen, MD
Abstract: Melanoma treatment costs continue to rise. Sunscreen is a photoprotective tool that may reduce the incidence of melanoma but can be cost prohibitive for lower socioeconomic populations. New York State...
Abstract: Melanoma treatment costs continue to rise. Sunscreen is a photoprotective tool that may reduce the incidence of melanoma but can be cost prohibitive for lower socioeconomic populations. New York State...
...
04/22/2021
Journal of Clinical Pathways
News
Medicare FFS Pricing Incentivizes Use of Mohs Micrographic Surgery Over Other Skin Cancer Procedures
12/03/2020
12/03/2020
Journal of Clinical Pathways
Research in Review
Continued Nivolumab After Progression May Improve Outcomes in Melanoma
07/03/2017
Patients with advanced melanoma who are treated with nivolumab after their first disease progression may experience tumor response without compromising safety, according to an original investigation published in JAMA...
Patients with advanced melanoma who are treated with nivolumab after their first disease progression may experience tumor response without compromising safety, according to an original investigation published in JAMA...
...
07/03/2017
Journal of Clinical Pathways
Research in Review
Does Delayed Lymph Node Biopsy Affect Survival Rates in Melanoma?
06/29/2017
Recent research compared survival outcomes of patients newly diagnosed with melanoma who received a sentinel lymph node biopsy within 30 days and those who received biopsy after 30 days, published in the Journal of...
Recent research compared survival outcomes of patients newly diagnosed with melanoma who received a sentinel lymph node biopsy within 30 days and those who received biopsy after 30 days, published in the Journal of...
Recent...
06/29/2017
Journal of Clinical Pathways
Research in Review
Imaging Needed to Monitor Melanoma Brain Metastases During PD-1 Therapy
06/03/2017
Central nervous system imaging is needed during programmed death 1 (PD-1) inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases, according to research presented at...
Central nervous system imaging is needed during programmed death 1 (PD-1) inhibitor therapy to monitor incidence, patterns of progression, and outcomes of melanoma brain metastases, according to research presented at...
...
06/03/2017
Journal of Clinical Pathways
Research in Review
Burden on Treatment Costs Impact Quality of Life Among Melanoma Survivors
06/03/2017
Financial toxicity and excessive financial burden appeared common among melanoma survivors, frequently leading to disease-related distress, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...
Financial toxicity and excessive financial burden appeared common among melanoma survivors, frequently leading to disease-related distress, according to research presented at the 2017 ASCO Annual Meeting (June 2-6,...
...
06/03/2017
Journal of Clinical Pathways
Research in Review
Advanced Melanoma Increases Psychological Burden in Patients
05/25/2017
Stage III and IV melanoma may have a profound impact on patients’ distress burden, which requires further intervention strategies, according to research that will be presented at the 2017 ASCO Annual Meeting...
Stage III and IV melanoma may have a profound impact on patients’ distress burden, which requires further intervention strategies, according to research that will be presented at the 2017 ASCO Annual Meeting...
Stage...
05/25/2017
Journal of Clinical Pathways

Expert Insights

Farberg
Videos
Co-Managing Advanced Skin Cancer: Immunotherapy Insights
01/25/2024
Aaron S. Farberg, MD
In this interview, Dr Aaron Farberg explored key factors in advanced basal cell carcinoma and cutaneous squamous cell carcinoma.
In this interview, Dr Aaron Farberg explored key factors in advanced basal cell carcinoma and cutaneous squamous cell carcinoma.
In this interview, Dr Aaron...
01/25/2024
The Dermatologist
NSCLC, non-small cell lung cancer
Interview
Reflex NGS and PD-L1 Testing Streamlines Biomarker Turnaround and Treatment Planning in Resectable NSCLC
01/27/2026
Tina Edmonston, MD; David D. Shersher, MD
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David D. Shersher discuss their findings on how implementing reflex next generation sequencing (NGS) and programmed death-ligand 1 (PD-L1) testing at diagnosis reduced biomarker turnaround time and supported faster...
Drs Tina B. Edmonston and David...
01/27/2026
Journal of Clinical Pathways
Woyach Headshot
Interview
Targeting BTK Mutations in CLL: Emerging Data on Rocbrutinib
12/18/2025
Jennifer Ann Woyach, MD
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early clinical findings on rocbrutinib, a dual-binding BTK inhibitor demonstrating promising activity and tolerability in heavily pretreated CLL, including in the presence of common resistance mutations.
This interview highlights early...
12/18/2025
Journal of Clinical Pathways
Joanna Rhodes, MD, MSCE
Interview
Transforming CLL Management: How MRD Could Shape Treatment Duration and Decision-Making
12/17/2025
Joanna M. Rhodes, MD, MSCE
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion, Joanna Rhodes, MD, MSCE, breaks down the promise and current limitations of MRD testing in chronic lymphocytic leukemia (CLL), exploring how it could one day refine treatment intensity, timing, and outcomes, and...
In this candid discussion,...
12/17/2025
Journal of Clinical Pathways
ONLINE EXCLUSIVES
Medicare and Cancer Care Reform: Closing the Gaps in Access and Affordability
12/15/2025
Youngmin Kwon
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral fellow Youngmin Kwon, PhD, discusses recent health care reforms and reveals how bold policy shifts are finally helping to close long-standing gaps in cancer-care access and affordability.
In this interview, postdoctoral...
12/15/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice: Part 2
12/04/2025
Houda Hachad, PharmD
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses how emerging US Food and Drug Administration (FDA) actions and expanding pharmacogenomic insights may soon transform fluoropyrimidine safety and reshape precision oncology from diagnosis through survivorship.
Houda Hachad, PharmD, discusses...
12/04/2025
Journal of Clinical Pathways
Houda Hachad, PharmD
Videos
Clinical Implications of the FDA’s Capecitabine Boxed Warning: Integrating DPYD Testing into Oncology Practice
12/04/2025
Houda Hachad, PharmD
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing may be just the beginning of a broader shift toward pharmacogenomics-driven safety in cancer treatment.
Learn why mandatory DPYD testing...
12/04/2025
Journal of Clinical Pathways
BDHC thumbnail
Videos
Breaking Down Cancer Prevention: What Really Works?
11/26/2025
John Hennessy, MBA; Michael Kolodziej, MD
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down Health Care, John Hennessy and Dr. Michael Kolodziej explore the crucial difference between cancer screening and true cancer prevention, highlighting how lifestyle changes, vaccines, and emerging therapies...
In this episode of Breaking Down...
11/26/2025
Cancer Care Business Exchange
Koulopoulos
Videos
Gigatrends Reshaping Global Health Care: Insights for CPC+CBEx 2025
10/31/2025
Thomas Koulopoulos
Futurist Thomas Koulopoulos explores how “gigatrends”—seismic global shifts like changing demographics and AI—are redefining health care, urging a balance between innovation and trust as the industry evolves toward more human-centered,...
Futurist Thomas Koulopoulos explores how “gigatrends”—seismic global shifts like changing demographics and AI—are redefining health care, urging a balance between innovation and trust as the industry evolves toward more human-centered,...
Futurist Thomas Koulopoulos...
10/31/2025
Journal of Clinical Pathways
Kwon Headshot
Interview
Medicare and Cancer Care Reform: Closing the Gaps in Access and Affordability
10/23/2025
Youngmin Kwon
Postdoctoral fellow Youngmin Kwon discusses how Medicare eligibility reduces financial barriers for cancer survivors, and why disparities in access and affordability still persist.
Postdoctoral fellow Youngmin Kwon discusses how Medicare eligibility reduces financial barriers for cancer survivors, and why disparities in access and affordability still persist.
Postdoctoral fellow Youngmin...
10/23/2025
Journal of Clinical Pathways
CONFERENCE COVERAGE
CAR T-Cell Therapy and Bispecifics in the Community: Opportunities and Obstacles
10/22/2025
Lavi Kwiatkowsky
At CPC+CBEx 2025, Lavi Kwiatkowsky discussed how payer frameworks, accreditation requirements, and operational challenges are shaping access to CAR T-cell and bispecific therapies in community oncology—and how technology could bridge the gap...
At CPC+CBEx 2025, Lavi Kwiatkowsky discussed how payer frameworks, accreditation requirements, and operational challenges are shaping access to CAR T-cell and bispecific therapies in community oncology—and how technology could bridge the gap...
At CPC+CBEx 2025, Lavi...
10/22/2025
Journal of Clinical Pathways

Newsfeed

Conference Coverage
Toxicity Costs Among Patients With Melanoma Receiving Ipilimumab and Nivolumab
07/14/2021
Study findings show the cost of toxicities among patients with metastatic melanoma receiving ipilimumab and nivolumab were small, encompassing 3% of total costs.
Study findings show the cost of toxicities among patients with metastatic melanoma receiving ipilimumab and nivolumab were small, encompassing 3% of total costs.
Study findings show the cost of...
07/14/2021
Journal of Clinical Pathways
Clinical Pathways NEXT, Free Webinar, CPC, Oncology Pathways
Press Release
HMP Global Launches Clinical Pathways NEXT to Address Real-Time Oncology Pathway Decision-Making
02/03/2026
As oncology innovation accelerates and evidence evolves faster than traditional pathway update cycles, stakeholders need clearer insight into how clinical pathways adapt in real time. Clinical Pathways NEXT, a new, free quarterly virtual...
As oncology innovation accelerates and evidence evolves faster than traditional pathway update cycles, stakeholders need clearer insight into how clinical pathways adapt in real time. Clinical Pathways NEXT, a new, free quarterly virtual...
As oncology innovation...
02/03/2026
Journal of Clinical Pathways
News
Adoptive Cell Therapy Advances Target Ovarian Cancer Solid Tumor Barriers
01/23/2026
Hannah Musick
A comprehensive review highlights emerging adoptive cell therapy strategies aimed at overcoming immune suppression, antigen heterogeneity, and safety challenges in ovarian cancer.
A comprehensive review highlights emerging adoptive cell therapy strategies aimed at overcoming immune suppression, antigen heterogeneity, and safety challenges in ovarian cancer.
A comprehensive review...
01/23/2026
Journal of Clinical Pathways
News
Medicare Advantage Reduces Use of High-Cost Cancer Drugs Compared With Traditional Medicare
01/22/2026
Lisa Kuhns, PhD, MD
Medicare Advantage (MA) enrollees with colorectal cancer (CRC) and advanced non–small cell lung cancer (NSCLC) were less likely than traditional Medicare (TM) beneficiaries to receive cancer-directed drugs and, when treated, were less likely...
Medicare Advantage (MA) enrollees with colorectal cancer (CRC) and advanced non–small cell lung cancer (NSCLC) were less likely than traditional Medicare (TM) beneficiaries to receive cancer-directed drugs and, when treated, were less likely...
Medicare Advantage (MA)...
01/22/2026
Journal of Clinical Pathways
News
Medicare Advantage Linked to Lower Access to High-Quality Cancer Surgery in US
01/19/2026
Grace Taylor, MS, MA
A national Medicare study found that patients enrolled in Medicare Advantage were significantly less likely than those in traditional Medicare to receive major cancer surgery at high-quality hospitals, highlighting potential network-related...
A national Medicare study found that patients enrolled in Medicare Advantage were significantly less likely than those in traditional Medicare to receive major cancer surgery at high-quality hospitals, highlighting potential network-related...
A national Medicare study found...
01/19/2026
Journal of Clinical Pathways
News
McKesson Report Details Key Trends Shaping US Community Oncology Care
01/14/2026
Grace Taylor, MS, MA
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community Oncology Report 2025 reveals how community oncology practices across the US are navigating rapid advances in precision medicine, clinical trials, and technology as they care for the majority of cancer patients.
McKesson’s Advancing Community...
01/14/2026
Journal of Clinical Pathways
News
2025 US Cancer Disparities Report Highlights Education, Rural Gaps
01/12/2026
Hannah Musick
The American Cancer Society’s 2025 report reveals that education level and rural residence drive larger US cancer mortality disparities than race alone, underscoring the central role of socioeconomic and geographic inequities across the...
The American Cancer Society’s 2025 report reveals that education level and rural residence drive larger US cancer mortality disparities than race alone, underscoring the central role of socioeconomic and geographic inequities across the...
The American Cancer Society’s...
01/12/2026
Journal of Clinical Pathways
News
Real-World Data Show Similar Outcomes for First-Line uHCC Immunotherapy Regimens
01/08/2026
Grace Taylor, MS, MA
Real-world data from 6 US cancer centers show no significant survival differences between atezolizumab/bevacizumab and durvalumab/tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC), with liver function...
Real-world data from 6 US cancer centers show no significant survival differences between atezolizumab/bevacizumab and durvalumab/tremelimumab as first-line therapy for unresectable hepatocellular carcinoma (uHCC), with liver function...
Real-world data from 6 US cancer...
01/08/2026
Journal of Clinical Pathways
News
CAR T Therapy Access Remains Uneven Despite Specialist Referral
01/07/2026
Grace Taylor, MS, MA
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred for chimeric antigen receptor T-cell (CAR T) therapy at a major academic cancer center never received treatment, with disease progression, limited product availability, and potential racial disparities...
Nearly half of patients referred...
01/07/2026
Journal of Clinical Pathways
Conference Coverage
Daratumumab Maintenance Deepens MRD Negativity After ASCT in Multiple Myeloma
12/22/2025
Juliet Gallagher
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD) status is an increasingly important prognostic marker in multiple myeloma. New data from the phase 3 AURIGA study, presented at ASH 2025, provide detailed insights into MRD dynamics following autologous stem...
Minimal residual disease (MRD)...
12/22/2025
Journal of Clinical Pathways
Conference Coverage
Biology-Based Strategies for Managing Iron Toxicity in Hematologic Disorders
12/19/2025
Grace Taylor, MS, MA
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology reveal that continuous suppression of toxic, reactive iron—rather than reduction of total iron stores—is critical for preventing organ damage and improving outcomes across transfusion-dependent hematologic...
New insights into iron biology...
12/19/2025
Journal of Clinical Pathways

Interactive Features

Quiz
Quiz: Ipilimumab for the Treatment of Metastatic Melanoma
07/29/2021
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line therapy regimens for patients with metastatic melanoma, those containing ipilimumab had the lowest total cost.
True or False: Across first-line...
07/29/2021
Journal of Clinical Pathways
Quiz
Regional Inequalities Persist in Lung Cancer Mortality Trends
11/19/2025
11/19/2025
Journal of Clinical Pathways
Quiz
Rural Health Transformation Program Fund Distribution
09/29/2025
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health Transformation Program, announced by CMS under the Working Families Tax Cuts Act, will allocate $50 billion beginning in fiscal year 2026, with funding distributed evenly across all states regardless of...
True or False: The Rural Health...
09/29/2025
Journal of Clinical Pathways
Quiz
Uncovering the True Cost of Care
09/18/2025
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable Cost of Care (PCOC) model and its applications in value-based care.
Learn more about the Predictable...
09/18/2025
Journal of Clinical Pathways
Quiz
Understanding the NCCN Guidelines Navigator
08/27/2025
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive Cancer Network (NCCN) Guidelines Navigator is a new interactive digital platform that delivers evidence-based oncology recommendations and is currently available for all 88 NCCN guideline sets.
The National Comprehensive...
08/27/2025
Journal of Clinical Pathways
Quiz
Specialty Palliative Care Trends for Medicare Beneficiaries
08/12/2025
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of the following trends was observed in the delivery of specialty palliative care (PC) among Medicare beneficiaries with poor-prognosis cancers?
Between 2018 and 2023, which of...
08/12/2025
Journal of Clinical Pathways
Quiz
Understanding the Role of Clinical Pathways in Oncology Care
07/30/2025
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical pathways are helping multidisciplinary teams standardize cancer care, reduce costs, and improve outcomes—and why aligning them with evidence-based guidelines is essential in today’s value-based healthcare...
Learn more about how clinical...
07/30/2025
Journal of Clinical Pathways
SPONSORED QUIZ BY SANOFI
Treatments in Multiple Myeloma
11/28/2022
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA (isatuximab-irfc) is indicated: In combination with carfilzomib and dexamethasone, for the treatment of adult patients with relapsed or refractory multiple myeloma who have received 1 to 3 prior lines of...
  Indication SARCLISA...
11/28/2022
Journal of Clinical Pathways
Quiz
Quiz: Medicaid Insurance and Biomarker Testing in NSCLC
07/26/2022
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid beneficiaries with advanced non-small cell lung cancer were less likely to receive biomarker testing and biomarker-driven therapies compared to those with commercial insurance.
True or False: Medicaid...
07/26/2022
Journal of Clinical Pathways
Quiz
Quiz: Comparing the Cost of Regimens in Newly Diagnosed Multiple Myeloma
07/14/2022
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among daratumumab, lenalidomide, and dexamethasone triple therapy (DRd); bortezomib and lenalidomide plus dexamethasone triple therapy (VRd); and Rd, the most cost-effective treatment regimen in patients with newly diagnosed...
True or False: Among...
07/14/2022
Journal of Clinical Pathways
Quiz
Quiz: Germline BRCA Testing in Ovarian Cancer
07/12/2022
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of commercially insured patients with ovarian cancer receive germline BRCA testing.
True or False: About 34% of...
07/12/2022
Journal of Clinical Pathways
JCP Nov-Dec Cover

Current Issue

December 2025
Volume 11
Issue 6
Current Issue
Issue Archive

Special Reports

Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
08/15/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
08/15/2025
Journal of Clinical Pathways
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
08/15/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
08/15/2025
Journal of Clinical Pathways
Special Report
Navigating the Management of Metastatic Colorectal Cancer in the Advanced Treatment Setting: Insights From an Expert Panel
06/12/2025
Tanios Bekaii-Saab, MD, FACP; Stacey Cohen, MD; Marwan Fakih, MD; Anwaar Saeed, MD
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the current treatment landscape and unmet needs in metastatic colorectal cancer (mCRC).
Review a special report on the...
06/12/2025
Journal of Clinical Pathways
Page 1
Special Report
Predictable Cost of Care Model for Treatment Decisions: Working Group Consensus Statements for Metastatic Non-Small Cell Lung Cancer
02/19/2025
Edward Arrowsmith, MD; Vishnukamal Golla, MD, MPH; Rhonda Henschel, MBA; Andrew Hertler, MD, FACP; David Jackman, MD; Gordon Kuntz; Olaf Lodbrok, MS, MBA; Carole Tremonti, RN, MBA; Lalan Wilfong, MD
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care Working Group developed a model that can be used by various entities evaluating the impact of treatment on the total cost of care.
The Predictable Cost of Care...
02/19/2025
Journal of Clinical Pathways
JCP Special Report
Recommendations for Creating an Oncology Clinical Pathways Framework Tool Based on Payer, Provider, and Patient Priorities: Findings From the 2021 Care Pathways Working Group
05/20/2022
Robin T. Zon, MD, FACP, FASCO; Gordon Kuntz; Winston Wong, PharmD
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways convened the 2021 Care Pathways Working Group to identify and reconcile the different pathway drivers for each stakeholder now and five years into the future, creating a framework tool based on oncology care...
The Journal of Clinical Pathways...
05/20/2022
Journal of Clinical Pathways

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use